Dishman Carbogen Amcis Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹851.40 crore, reflecting a quarter-on-quarter *(QoQ) increase of 18.28 per cent from ₹719.80 crore. This corresponds to a year-on-year *(YoY) growth of 18.85 per cent.
Operating Profit
Operating Profit stands at ₹161.80 crore, reflecting a quarter-on-quarter *(QoQ) increase of 43.05 per cent from ₹113.11 crore. This corresponds to a year-on-year *(YoY) growth of 14.80 per cent.
PBDT
PBDT stands at ₹134.92 crore, reflecting a quarter-on-quarter *(QoQ) increase of 82.37 per cent from ₹73.98 crore. This corresponds to a year-on-year *(YoY) growth of 26.34 per cent.
Profit Before Tax
Profit Before Tax stands at ₹46.13 crore, reflecting a quarter-on-quarter *(QoQ) increase of 541.86 per cent from ₹-10.44 crore. This corresponds to a year-on-year *(YoY) growth of 66.53 per cent.
Net Profit
Net Profit stands at ₹21.74 crore, reflecting a quarter-on-quarter *(QoQ) increase of 267.62 per cent from ₹-12.97 crore. This represents a 49.55 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Dishman Carbogen Amcis Ltd Earnings
- YOY
- QOQ
Dishman Carbogen Amcis Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Dishman Carbogen Amcis Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Dishman Carbogen Amcis Ltd Financial Reports
Dishman Carbogen Amcis Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Dishman Carbogen | 2.56% | -3.66% | 9.20% | 5.17% | -9.29% | -22.99% |
| SMS Pharma. | -1.10% | -0.96% | 0.09% | -5.00% | 26.74% | 58.70% |
| Advanced Enzyme | 1.49% | -0.52% | -1.69% | -4.08% | 18.40% | -6.98% |
| Morepen Labs. | 2.85% | -7.62% | -1.52% | 24.57% | 58.91% | -6.52% |
| Kwality Pharma | 4.16% | 0.46% | 2.18% | 73.81% | 163.64% | 151.29% |
| Panacea Biotec | -2.08% | -19.81% | -20.29% | 19.30% | 27.01% | 9.14% |
| Hikal | 2.57% | -4.61% | 1.09% | 14.71% | 11.79% | -32.88% |
Company Info
Company Information
WTD & Executive Director : Deohooti J Vyas
ED / Global MD / Promoter : Arpit J Vyas
Independent Non Exe. Director : KULIN NALINKANT SHAH
Independent Non Exe. Director : Hemantkumar J Bhatt
Independent Non Exe. Director : Margie S Parikh
Non-Exec & Non-Independent Dir : Dhaval R. Shah
Company Sec. & Compli. Officer : Shrima Dave